Skip to main content

ORION: A Global, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy

Lead Author: Günter Höglinger, MD (Presenter)

Published: AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)

Date: March 5 - 9, 2024

Read more (opens new window)

Findings From a Pharmacokinetic and Pharmacodynamic Study of Sodium Phenylbutyrate and Taurursodiol in Participants With Amyotrophic Lateral Sclerosis

Lead Author: James Wymer, MD (Presenter)

Published: 2024 MDA Clinical & Scientific Conference (MDA)

Date: March 3 - 6, 2024

Read more (opens new window)

Next Steps in Development for AMX0114: An Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration

Lead Author: Joshua Cohen

Published: 2024 MDA Clinical & Scientific Conference (MDA)

Date: March 3 - 6, 2024

Read more (opens new window)

A Joint Model for Assessing Mortality-Adjusted Progression (MAP) in Amyotrophic Lateral Sclerosis: Application to Clinical Trials of Sodium Phenylbutyrate and Taurursodiol

Lead Author: Ruben van Eijk

Published: International Symposium on ALS/MND (MNDA)

Date: December 6 - 8, 2023

Read more (opens new window)

Effect of Sodium Phenylbutyrate and Taurursodiol on Plasma Concentrations of Neuroinflammatory Biomarkers in Amyotrophic Lateral Sclerosis: Results From the CENTAUR Trial

Lead Author: Robert Bowser, PhD & Jiyan An

Published: Journal of Neurology, Neurosurgery and Psychiatry

Date: December 2, 2023

Read more (opens new window)

Rethinking Economic Evaluation in Amyotrophic Lateral Sclerosis Treatment: Embracing Alternative Model Conceptualizations

Lead Author: Sara Öhrman (Presenter)

Published: International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

Date: November 12 - 15, 2023

Read more (opens new window)

Proteomic Analyses in the 24-Week PEGASUS Trial Using the Olink Platform: Providing Insight Into the Biologic Activity of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease

Lead Author: Lahar Mehta, MD (Presenter)

Published: Clinical Trials on Alzheimer’s Disease (CTAD)

Date: October 24 - 27, 2023

Read more (opens new window)

Design of a Global Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy (A35-009 ORION)

Lead Author: Günter Höglinger, MD

Published: Neuro2023

Date: October 19 - 20, 2023

Read more (opens new window)

Analysis of Sodium Phenylbutyrate and Taurursodiol Survival Effect in ALS Using External Controls

Lead Author: Sabrina Paganoni, MD, PhD & Melanie Quintana, PhD

Published: Annals of Clinical and Translational Neurology

Date: October 9, 2023

Read more (opens new window)

An In Vitro Recovery Study of Sodium Phenylbutyrate and Taurursodiol From 3 Types of Dosing Containers and Various Percutaneous Endoscopic Gastrostomy Feeding Tubes

Lead Author: Machelle Manuel, PhD

Published: Northeast ALS Consortium Annual Meeting (NEALS)

Date: October 4 - 6, 2023

Read more (opens new window)